Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2016
Immune checkpoint inhibition is a novel approach to cancer treatment with enormous potential to improve the outcomes of patients with a range of malignancies. However, owing to this novel approach, a range of adverse events have emerged with different aetiologies to those of more conventional cancer treatments. In this Review, the authors describe the occurrence, and optimal management of adverse events resulting from use of immune checkpoint inhibitors.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
103
References
538
Citations
NaN
KQI